Why Patient-Focused Drug Development Should Drive Corporate Strategy
The FDA's patient-focused guidance is a strategic framework, not a compliance exercise. Companies that define patient value early build durable commercial advantage.
In Vivo - August 11, 2026

Dopl To Bring Remote Robotic Telecardiac Ultrasound To Rural Areas, Eyes Q3 2027 FDA Clearance
Dopl has raised $8m to date and plans to use the latest $6.3m to pursue FDA 510(k) clearance for its Traverse robotic teleultrasound system, targeting Q3 2027 clearance. CEO Ryan James envisions building a hardware-agnostic system that can integrate with existing robots.
Medtech Insight - August 11, 2026

GLP-1 And Consumer Health – Which Categories Win And Which Lose?
IQVIA Consumer Health sets out which categories will win and which will lose as GLP-1 weight loss drugs reshape demand, with slimming and detox products most exposed and protein and gastrointestinal support best placed.
HBW Insight - August 11, 2026

Seeking faster oversight, notified bodies request full access to EU medtech database
Team-NB says data from EUDAMED is vital for comprehensive risk-based surveillance.
Medtech Insight - August 11, 2026

Sweden’s Medicover Exits India After KKR Acquires Hospital Network Valued At $1.39bn
KKR is paying $1.39bn for a controlling stake in Medicover India's 24-hospital network, betting on India's consolidating hospital market even as the business it is buying posted a net loss and sits at a 46x EBITDA valuation.
Medtech Insight - August 11, 2026

Samsung Bioepis Launches Eylea Pre-Filled Syringe Biosimilar In Europe
Opuviz is now available in Europe in both vial and pre-filled syringe presentations, completing Samsung Bioepis' ophthalmology offering in the growing aflibercept market.
Generics Bulletin - August 11, 2026

Aveva Clears Appeals Hurdle In Bid To Launch Only Approved ZTlido Generic
Aveva’s only approved generic version of ZTlido has moved closer to potential US market entry after the Federal Circuit upheld a finding that its lidocaine patch does not infringe three Scilex patents.
Generics Bulletin - August 11, 2026

FDA Remediation Puts Third Of Amphastar Sales Under Spotlight
Amphastar is bracing for higher costs and some sales pressure as it remediates its FDA-cited IMS facility, while newer generics support growth and the company keeps its insulin aspart biosimilar on track for a potential 2027 launch.
Generics Bulletin - August 11, 2026

Biocon’s ‘Unique Play’ Leaves It Bullish On US Eylea Biosimilar
Biocon expects to make the headstart for its Eylea biosimilar in the US count and indicates that its product pipeline stands to gain from recent regulatory streamlining.
Generics Bulletin - August 11, 2026

Strategic Intent: First-in-class, two markets: Annexon’s GBS and GA Strategies
On the inaugural episode of the Strategic Intent video podcast, Annexon CEO Doug Love discusses commercializing tanruprubart in GBS and vonaprument in GA, building dual launch teams, oral complement strategy, and MFN-driven partnering and pricing considerations.
In Vivo - August 11, 2026

Europe May Follow France’s Biosimilar Lead, Germany Reforms Cut Both Ways: Lupin CEO
France’s model of incentivizing biosimilars substitution to aid innovator drug purchases could be worthy of emulation while Germany’s recently announced changes cut both ways, says Lupin’s CEO Vinita Gupta as she also talks of South Africa semaglutide launch plans.
Scrip - August 11, 2026

Stock Watch: Why Investors Sold Sanofi Despite The Headline Beat
Sanofi's second quarter was strong on paper, but a Dupixent gross-to-net one-off, a stumbling vaccine franchise, and a weaker second-half outlook sent the stock down nearly 9% in Paris on results day.
Scrip - August 11, 2026

‘Ozempic Face’ Fix: Start GLP-1s With Proper Skin Care – Galderma Chief Science Officer
As tens of millions of consumers reach for weight-loss drugs, Galderma's Chief Scientific Officer says the skin consequences are real — and the company already is seeing solutions in clinical trials.
HBW Insight - August 11, 2026